Strides Pharma Science's shares traded in the red on October 6, 2023, following a 1.5% change in the company's equity ownership 

Approximately 13.75 lakh shares of the company were traded on that day, totaling Rs 65.1 crore in value 

The average trading price per share was Rs 502, representing a 1.4% discount from the previous day's closing price of Rs 508.90 

On October 4, Strides Pharma announced that its subsidiary, Strides Pharma Global, had received approval from the USFDA for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumarate (300mg) tablets, known as EET tablets 

These EET tablets will be produced at the company's Bengaluru facility and have a market opportunity estimated at $7.5 million 

As of June 30, the company's promoters held a 28.1% stake, while foreign institutional investors (FIIs) held 16.72%, domestic institutional investors (DIIs) held 20%, and the public held a 35.2% stake in Strides Pharma 

Over the past year, Strides Pharma's shares have surged by more than 46.8%, outperforming the Nifty 50 index, which returned 13.7% 

At the close of trading at 3:30 pm, Strides Pharma's shares were valued at Rs 501, marking a 1.55% decrease from the previous day's closing price on the NSE 

The trading activity on October 6 was marked by the significant exchange of shares, reflecting investor interest and market dynamics 

Strides Pharma's recent USFDA approval for EET tablets and its strong one-year performance indicate its position as a noteworthy player in the pharmaceutical industry